CA2671607A1 - Imidazopyridine inhibitors of iap - Google Patents
Imidazopyridine inhibitors of iap Download PDFInfo
- Publication number
- CA2671607A1 CA2671607A1 CA002671607A CA2671607A CA2671607A1 CA 2671607 A1 CA2671607 A1 CA 2671607A1 CA 002671607 A CA002671607 A CA 002671607A CA 2671607 A CA2671607 A CA 2671607A CA 2671607 A1 CA2671607 A1 CA 2671607A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- heterocycle
- carbocycle
- compound
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- -1 amino, cyano, nitro, amidino, guanidino Chemical group 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical group 0.000 claims 12
- 125000002252 acyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 230000001640 apoptogenic effect Effects 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 claims 1
- VTBOTOBFGSVRMA-UHFFFAOYSA-N 1-Methylcyclohexanol Chemical compound CC1(O)CCCCC1 VTBOTOBFGSVRMA-UHFFFAOYSA-N 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- HCFRWBBJISAZNK-UHFFFAOYSA-N 4-Hydroxycyclohexylcarboxylic acid Chemical compound OC1CCC(C(O)=O)CC1 HCFRWBBJISAZNK-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 241001061127 Thione Species 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 1
- 229960004039 finasteride Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87082106P | 2006-12-19 | 2006-12-19 | |
| US60/870,821 | 2006-12-19 | ||
| PCT/US2007/087532 WO2008079735A1 (en) | 2006-12-19 | 2007-12-14 | Imidazopyridine inhibitors of iap |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2671607A1 true CA2671607A1 (en) | 2008-07-03 |
Family
ID=39361343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002671607A Abandoned CA2671607A1 (en) | 2006-12-19 | 2007-12-14 | Imidazopyridine inhibitors of iap |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8063218B2 (enExample) |
| EP (1) | EP2125809A1 (enExample) |
| JP (1) | JP2010513561A (enExample) |
| KR (1) | KR20090094461A (enExample) |
| CN (1) | CN101605786A (enExample) |
| AU (1) | AU2007337104A1 (enExample) |
| BR (1) | BRPI0719481A2 (enExample) |
| CA (1) | CA2671607A1 (enExample) |
| IL (1) | IL198927A0 (enExample) |
| NZ (1) | NZ577150A (enExample) |
| RU (1) | RU2466131C2 (enExample) |
| WO (1) | WO2008079735A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2574040C (en) | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
| KR101278732B1 (ko) * | 2004-12-20 | 2013-07-09 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| US7517906B2 (en) | 2005-02-25 | 2009-04-14 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
| EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
| US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| JP2009512719A (ja) | 2005-10-25 | 2009-03-26 | アエゲラ セラピューティクス インコーポレイテッド | Ｉａｐｂｉｒドメイン結合化合物 |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| JP5419685B2 (ja) | 2006-05-16 | 2014-02-19 | ファーマサイエンス・インコーポレイテッド | Ｉａｐｂｉｒドメイン結合タンパク質 |
| US20100143499A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| MX2009000824A (es) * | 2006-07-24 | 2009-02-04 | Tetralogic Pharmaceuticals Cor | Antagonistas dimericos de las proteinas inhibidoras de la apoptosis. |
| US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014252A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
| US20100113326A1 (en) * | 2006-07-24 | 2010-05-06 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| RU2491276C2 (ru) * | 2007-04-30 | 2013-08-27 | Дженентек, Инк. | Ингибиторы iap |
| CA2686638A1 (en) * | 2007-05-07 | 2008-11-13 | Tetralogic Pharmaceuticals Corp. | Tnf.alpha. gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins |
| MX2010007543A (es) * | 2008-01-11 | 2010-09-30 | Genentech Inc | Inhibidores de iap. |
| AU2009279924B2 (en) | 2008-08-02 | 2014-10-02 | Genentech, Inc. | Inhibitors of IAP |
| CA2730357A1 (en) * | 2008-08-16 | 2010-02-25 | Genetech, Inc. | Azaindole inhibitors of iap |
| US8283372B2 (en) * | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US20110034469A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Heterocyclic Compound |
| RU2554087C2 (ru) | 2009-12-18 | 2015-06-27 | Айденикс Фармасьютикалз, Инк. | 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с |
| KR20120140658A (ko) | 2010-02-12 | 2012-12-31 | 파마사이언스 인크. | Ｉａｐ ｂｉｒ 도메인 결합 화합물 |
| US8835458B2 (en) | 2010-08-31 | 2014-09-16 | Hanmi Science Co., Ltd | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells |
| KR20140011773A (ko) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 이중 저해 활성을 갖는 헤테로고리 유도체 |
| BR112020009369A2 (pt) * | 2017-11-13 | 2020-10-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | miméticos de smac usados como inibidores de iap e seus usos |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| CA3132740A1 (en) * | 2019-03-07 | 2020-09-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination of iap inhibitor and immune checkpoint inhibitor |
| JP7587526B2 (ja) * | 2019-05-10 | 2024-11-20 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法 |
| EP4006037A4 (en) | 2019-07-31 | 2023-12-13 | Fimecs, Inc. | HETEROCYCLIC COMPOUND |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE430062B (sv) | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
| DE2714880A1 (de) | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP0217634B1 (en) | 1985-09-26 | 1992-06-10 | Beckman Research Institute of the City of Hope | Sequencing of peptides |
| US4935494A (en) | 1988-11-15 | 1990-06-19 | City Of Hope | C-terminal peptide and protein sequencing |
| DK167813B1 (da) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| WO1992001938A1 (en) | 1990-07-20 | 1992-02-06 | City Of Hope | Derivatization of c-terminal proline |
| EP0669836B1 (en) | 1992-11-13 | 1996-07-03 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| US5559209A (en) | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6472172B1 (en) | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
| WO2000039585A1 (en) | 1998-12-28 | 2000-07-06 | Sunesis Pharmaceuticals, Inc. | Identifying small organic molecule ligands for binding |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| AU2001286730A1 (en) | 2000-08-24 | 2002-03-04 | Thomas Jefferson University | An iap binding peptide or polypeptide and methods of using the same |
| US6992063B2 (en) | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
| WO2002026775A2 (en) | 2000-09-29 | 2002-04-04 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
| WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
| AU2002253908A1 (en) | 2001-02-08 | 2003-02-17 | Thomas Jefferson University | A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis |
| MXPA03010762A (es) | 2001-05-31 | 2005-03-07 | Univ Princeton | Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap. |
| WO2003040172A2 (en) | 2001-11-09 | 2003-05-15 | Aegera Therapeutics, Inc. | Methods and reagents for peptide-bir interaction screens |
| WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| AU2003249920A1 (en) | 2002-07-02 | 2004-01-23 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| ES2318167T3 (es) | 2002-07-15 | 2009-05-01 | The Trustees Of Princeton University | Compuestos de union a iap. |
| AU2003290083A1 (en) | 2002-08-13 | 2004-03-11 | Cell Center Cologne Gmbh | Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin's lymphomas |
| US20040171554A1 (en) | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
| EP1590666B1 (en) | 2003-02-07 | 2008-07-09 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
| IL156263A0 (en) | 2003-06-02 | 2004-01-04 | Hadasit Med Res Service | Livin-derived peptides, compositions and uses thereof |
| SE0301904D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | Novel imidazopyridine compound II with therapeutic effect |
| US7067274B2 (en) | 2003-11-13 | 2006-06-27 | Genentech, Inc. | Compositions and methods for the screening pro-apoptotic compounds |
| CA2582734C (en) | 2004-03-01 | 2011-05-03 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| AU2005231956B2 (en) * | 2004-04-07 | 2009-11-05 | Novartis Ag | Inhibitors of IAP |
| SI1778718T1 (sl) | 2004-07-02 | 2015-01-30 | Genentech, Inc. | Inhibitorji IAP |
| CA2574040C (en) | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
| KR101278732B1 (ko) * | 2004-12-20 | 2013-07-09 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| CN1808446A (zh) * | 2005-01-22 | 2006-07-26 | 鸿富锦精密工业（深圳）有限公司 | 高速电路中耦合传输线等效模型的撷取方法 |
| US7517906B2 (en) | 2005-02-25 | 2009-04-14 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
| NZ594746A (en) * | 2005-12-19 | 2013-03-28 | Genentech Inc | Inhibitors of iap |
| PE20110224A1 (es) * | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
| KR20090065548A (ko) * | 2006-10-12 | 2009-06-22 | 노파르티스 아게 | Ｉａｐ 억제제로서의 피롤리딘 유도체 |
-
2007
- 2007-12-14 EP EP07865673A patent/EP2125809A1/en not_active Withdrawn
- 2007-12-14 WO PCT/US2007/087532 patent/WO2008079735A1/en not_active Ceased
- 2007-12-14 US US12/520,205 patent/US8063218B2/en not_active Expired - Fee Related
- 2007-12-14 JP JP2009543099A patent/JP2010513561A/ja not_active Ceased
- 2007-12-14 AU AU2007337104A patent/AU2007337104A1/en not_active Abandoned
- 2007-12-14 KR KR1020097014996A patent/KR20090094461A/ko not_active Ceased
- 2007-12-14 CA CA002671607A patent/CA2671607A1/en not_active Abandoned
- 2007-12-14 RU RU2009127800/04A patent/RU2466131C2/ru not_active IP Right Cessation
- 2007-12-14 CN CNA2007800473412A patent/CN101605786A/zh active Pending
- 2007-12-14 NZ NZ577150A patent/NZ577150A/en not_active IP Right Cessation
- 2007-12-14 BR BRPI0719481-1A patent/BRPI0719481A2/pt not_active IP Right Cessation
-
2009
- 2009-05-25 IL IL198927A patent/IL198927A0/en unknown
-
2011
- 2011-09-26 US US13/245,531 patent/US20120015974A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008079735A1 (en) | 2008-07-03 |
| CN101605786A (zh) | 2009-12-16 |
| IL198927A0 (en) | 2010-02-17 |
| NZ577150A (en) | 2012-04-27 |
| US20100130539A1 (en) | 2010-05-27 |
| US20120015974A1 (en) | 2012-01-19 |
| KR20090094461A (ko) | 2009-09-07 |
| AU2007337104A1 (en) | 2008-07-03 |
| JP2010513561A (ja) | 2010-04-30 |
| BRPI0719481A2 (pt) | 2014-02-11 |
| US8063218B2 (en) | 2011-11-22 |
| RU2009127800A (ru) | 2011-01-27 |
| EP2125809A1 (en) | 2009-12-02 |
| RU2466131C2 (ru) | 2012-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2671607A1 (en) | Imidazopyridine inhibitors of iap | |
| RU2008129683A (ru) | Ингибиторы iap | |
| JP2010513561A5 (enExample) | ||
| JP2009520041A5 (enExample) | ||
| RU2009144094A (ru) | Ингибиторы iap | |
| JP2010526079A5 (enExample) | ||
| JP2008524333A5 (enExample) | ||
| JP2007530553A5 (enExample) | ||
| JP2011529962A5 (enExample) | ||
| JP2011251990A5 (enExample) | ||
| RU2010133548A (ru) | Ингибиторы iap | |
| EP2090577A3 (en) | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | |
| AR098673A1 (es) | Herbicidas de pirrolidinona | |
| ZA200710975B (en) | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway | |
| EP2671581A3 (en) | Compositions and methods for treating cancer | |
| EA200601125A1 (ru) | 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы | |
| AR069368A1 (es) | Mezclas fungicidas | |
| ATE549336T1 (de) | Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer | |
| RU2008123839A (ru) | Соединение оксазола и фармацевтическая композиция | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| EA200700189A1 (ru) | Производные хиназолина в качестве ингибиторов parp | |
| JP2011523651A5 (enExample) | ||
| EA201071078A1 (ru) | Новые производные карбазола, являющиеся ингибиторами hsp90, содержащие их композиции и их применение | |
| AR104420A1 (es) | Butirolactonas como herbicidas | |
| AU2025202675A1 (en) | Conjugate molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| EEER | Examination request |
Effective date: 20121214 |
|
| FZDE | Discontinued |
Effective date: 20141216 |